Rheumatologists Refined Treatment Protocols for Lung Disease
New guidance helps patients with systemic sclerosis understand their risk for lung disease progression.
Updated on Oct. 5, 2026 in Asthma
Live Poll
Do you trust that current medical research is making sufficient progress in treating autoimmune lung diseases?
Rheumatologists have reviewed treatment protocols for interstitial lung disease in patients with systemic sclerosis. This shift aims to better identify individuals at the highest risk for lung function decline.
Why it matters
Identifying the subset of patients with systemic sclerosis who are likely to experience disease progression is critical for timely intervention. These updated protocols prioritize early screening to manage long-term lung health more effectively.
Clinical guidelines indicate that while interstitial lung disease may affect up to 90% of systemic sclerosis patients, progression occurs in 15% to 20% of cases. Research highlights that patients diagnosed within 5 years face a higher risk for disease progression.
The players
Congress of Clinical Rheumatology West
A professional medical forum for specialists to review research and treatment standards.
The details
Clinicians utilize baseline pulmonary function tests and CT scans to screen for interstitial lung disease. Treatment is frequently initiated with mycophenolate mofetil as a first-line therapy, though protocols are adjusted to address specific manifestations like skin, muscle, or joint involvement. For patients who show ongoing progression, rituximab may be considered, while recent findings from the FIBRONEER-ILD study suggest nerandomilast could improve forced vital capacity.
Timeline
October 2, 2026, marked the presentation of guidelines at the Congress of Clinical Rheumatology West.
Health Landscape
The clinical approach to systemic sclerosis-related lung disease is shifting toward targeted, early interventions based on specific risk factors. The FIBRONEER-ILD study trial results show how emerging therapeutic options are expanding the treatment landscape for progressive lung diseases.
Patients with systemic sclerosis should discuss their personal risk of interstitial lung disease progression with their doctor, particularly if they were diagnosed within the last 5 years. Regular pulmonary function tests and CT scans are essential tools for monitoring lung health over time.
The takeaway
Early identification of lung disease progression is the most effective way to preserve pulmonary function in systemic sclerosis. Ask your rheumatologist about your current screening schedule and whether your specific clinical profile requires more frequent monitoring.
Further reading
For more on managing respiratory health and chronic conditions, visit our Asthma section.
Source note: This article includes information reported by Healio.
Live Poll
Do you trust that current medical research is making sufficient progress in treating autoimmune lung diseases?
